The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
Displaying 101 - 120 of 1400
FTC Again Charges Endo and Impax with Illegally Preventing Competition in U.S. Market for Oxymorphone ER
FTC Staff Comment to Department of Veterans Affairs Concerning Authority of VA Professionals to Practice Healthcare
Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding the Commission’s Advocacy to the Department of Veterans Affairs
FTC Comment to Department of Veterans Affairs Supports Agency’s Interim Final Rule on VA Professionals’ Authority to Practice Health Care
Dissenting Statement of Commissioner Rohit Chopra Regarding the Commission's Advocacy to the Department of Veterans Affairs
Dissenting Statement of Commissioner Rebecca Kelly Slaughter Regarding the FTC Staff Comment on the VA's Interim Final Rule on the Authority of VA Professionals to Practice Health Care
Joint Statement of Commissioner Rohit Chopra and Commissioner Rebecca Kelly Slaughter Concurring in Part, Dissenting in Part, In the Matter of Flo Health, Inc.
Developer of Popular Women’s Fertility-Tracking App Settles FTC Allegations that It Misled Consumers About the Disclosure of their Health Data
The Federal Trade Commission filed an administrative complaint, and authorized a suit in federal court, to block the proposed $350 million acquisition by Memphis-based Methodist Le Bonheur Healthcare of two Memphis-area hospitals, known as Saint Francis, owned by Dallas-based healthcare system Tenet Healthcare Corporation. The complaint alleges that the proposed acquisition would substantially lessen competition in the Memphis area for a broad range of inpatient medical and surgical diagnostic and treatment services that require an overnight hospital stay, known as inpatient general acute care services, sold to commercial insurers and their insured members. According to the complaint, if the proposed acquisition is consummated, healthcare costs will rise, and the incentive to expand service offerings, invest in technology, improve access to care, and focus on quality of health care provided in the Memphis area will diminish. On Dec. 23, 2020, the parties announced that they were abandoning the acquisition.
Statement of Daniel Francis, Deputy Director of the FTC’s Bureau of Competition, Regarding the Announcement that Methodist Le Bonheur Healthcare has Abandoned Its Proposed Acquisition of Two Memphis-area Hospitals from Tenet Healthcare
FTC Approves Final Order Imposing Conditions on Stryker Corp.’s Acquisition of Wright Medical Group N.V.
Displaying 101 - 120 of 1400